Shanghai Henlius Biotech (HKSE:02696) Purchase Of Investment : HK$0 Mil (TTM As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Shanghai Henlius Biotech Purchase Of Investment?

Shanghai Henlius Biotech's purchase of investment for the three months ended in Jun. 2024 was HK$0 Mil. It means Shanghai Henlius Biotech spent HK$0 Mil on purchasing investments. Shanghai Henlius Biotech's purchase of investment for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0 Mil.

Compared with last quarter (HK$0 Mil in Dec. 2023 ), Shanghai Henlius Biotech spent the same money on purchasing investments in Jun. 2024 (HK$0 Mil).

Shanghai Henlius Biotech Purchase Of Investment Historical Data

The historical data trend for Shanghai Henlius Biotech's Purchase Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Henlius Biotech Purchase Of Investment Chart

Shanghai Henlius Biotech Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Purchase Of Investment

Get a 7-Day Free Trial

-131.25

Shanghai Henlius Biotech Quarterly Data
	Dec17	Mar18	Jun18	Dec18	Mar19	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Jun24
Purchase Of Investment	Get a 7-Day Free Trial													-	-	-	-	-

Shanghai Henlius Biotech Purchase Of Investment Calculation

Purchase of Investments represents cash outflow on the purchase of investments in securities.

Purchase Of Investment for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0 Mil.

Shanghai Henlius Biotech Purchase Of Investment Related Terms

Thank you for viewing the detailed overview of Shanghai Henlius Biotech's Purchase Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Henlius Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Henlius Biotech Inc (HKSE:02696) » Definitions » Purchase Of Investment

Comparable Companies

Traded in Other Exchanges

N/A

Address

B8 Building, No. 188 Yizhou Road, 11th Floor, Xuhui District, Shanghai, CHN, 200233

Website

https://www.henlius.com

Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and innovative biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China and Overseas. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.

Executives

Qatar Investment Authority	2201 Interest of corporation controlled by you
Fosun Industrial Co., Limited	2101 Beneficial owner
Shanghai Fosun Pharmaceutical (group) Co., Ltd.	2201 Interest of corporation controlled by you
Fosun Holdings Limited	2201 Interest of corporation controlled by you
Fosun International Holdings Ltd.	2201 Interest of corporation controlled by you
Fosun International Limited	2201 Interest of corporation controlled by you
Guo Guangchang	2201 Interest of corporation controlled by you
Shanghai Fosun High Technology (group) Co., Ltd.	2201 Interest of corporation controlled by you
Liu Scott Shi-kau	2201 Interest of corporation controlled by you
Jiang Wei-dong	2201 Interest of corporation controlled by you
Henlius Biopharmaceuticals, Inc.	2101 Beneficial owner

Shanghai Henlius Biotech Headlines

No Headlines